San Jose, CA, United States of America

Amanda Noel Chargin

USPTO Granted Patents = 6 

 

Average Co-Inventor Count = 3.3

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2019-2025

Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: Amanda Noel Chargin: Innovator in Neoplastic Cell Assays

Introduction

Amanda Noel Chargin is a prominent inventor based in San Jose, California. She has made significant contributions to the field of medical diagnostics, particularly in the assessment of neoplastic and neoplasia-related cells. With a total of six patents to her name, Amanda's work is at the forefront of cancer research and treatment methodologies.

Latest Patents

Among her latest patents, Amanda has developed methods for assaying neoplastic cells and neoplasia-related cells. These methods involve detecting heterogeneity, programmed-death ligand 1 (PD-L1) expression, and proliferation of neoplasia-related cells. The techniques include cytometric assays to quantify various parameters, which can help determine the presence of neoplastic cells in samples. Additionally, she has patented methods for assessing cellular breast samples, which utilize flow cytometry to obtain and analyze sample data.

Career Highlights

Amanda is currently associated with Incelldx, Inc., where she continues to innovate in the field of cellular diagnostics. Her work has the potential to significantly impact cancer treatment by providing more accurate assessments of cellular conditions.

Collaborations

Amanda collaborates with notable professionals in her field, including Keith Shults and Bruce K Patterson. Their combined expertise enhances the research and development of advanced diagnostic methods.

Conclusion

Amanda Noel Chargin is a trailblazer in the realm of neoplastic cell assays, with her innovative patents paving the way for improved cancer diagnostics and treatment options. Her contributions are invaluable to the medical community and continue to inspire future advancements in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…